Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

O-PTM-BIOMARKERS

Financiado

Cerrado

Discovery of novel cancer serum biomarkers based on aberrant post translational...

Discovery of novel cancer serum biomarkers based on aberrant post translational modifications of O glycoproteins O PTM Biomarkers and their application to early detection of cancer Early detection accomplished through an efficient screening programme remains the most promising approach to improve the long-term survival of cancer patients. Therefore there is a pressing need for the development of biomarkers,... ver más

31/03/2011

KINGS COLLEGE LOND...

4M€

Presupuesto del proyecto: 4M€

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 9 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2011-03-31 No tenemos la información de la convocatoria

0% 74% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

9 Participantes

KINGS COLLEGE LONDON

0.00€ | Lider

UNIVERSITY COLLEGE LONDON

RHUL

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

BIO2010-16922 GLICOSILACION ALTERADA EN CANCER: GLICOPROTEINAS Y GLICOSILT... 88K€ Cerrado

EARLYDETECT Development of an accurate early diagnostic tool for ovaria... 150K€ Cerrado

GLYCOSURF Surface Based Molecular Imprinting for Glycoprotein Recognit... 2M€ Cerrado

SweetCancerTest Diagnostics of aberrant cancer glycosylation signatures Cerrado

GlyCan Innovative Glycan based analysis for Cancer diagnostics 71K€ Cerrado

GLYCOBIOM Tools for the Detection of Novel Glyco biomarkers 7M€ Cerrado

Líder del proyecto

KINGS COLLEGE LONDON No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 4M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Early detection accomplished through an efficient screening programme remains the most promising approach to improve the long-term survival of cancer patients. Therefore there is a pressing need for the development of biomarkers, which detect the early changes for cancers where clinical symptoms only appear when the cancer has progressed, and treatment is ineffective. Our proposal, which addresses this problem at the European level, combines two unique features: i) large unique collections of sera with the potential for evaluation of diagnostic serum biomarkers with high statistical power, and ii) a novel technological approach involving specific immuno-detection of cancer-associated Post-Translationally Modified (PTM) glycoproteins in serum and of auto-antibodies to these glycoproteins. Glycosylation of proteins is one of the most abundant and complex forms of post translation modifications and the most important for the cell surface and secreted proteomes. O-glycosylation (O-PTM) is always altered in carcinomas, creating novel O-PTM epitopes which induce auto-antibodies. Our Main Objectives are therefore to:- 1.Use a novel glycopeptide microarray technology to identifiy, evaluate and validate an O-PTM auto-antibody signature as an early diagnostic biomarker, focusing on breast, ovarian, pancreatic and lung cancers. 2. Develop and validate novel ELISA-type assays for cancer specific glycoforms of the MUC1 and MUC16 glycoproteins (targets of current serum biomarker assays). The project brings together a Consortium with participants from 5 member States to fully exploit the potential of the unique serum banks at a European level by A. Integrating the expertise of world leaders in Glycobiology with Cancer Physicians and experts in biomarker assays. B. Establishing a functional interaction between Academic groups and Commercial enterprises committed to improving cancer therapy and diagnosis.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores